Cerecor, Sanford Burnham Prebys ink deal on immune program

By The Science Advisory Board staff writers

June 23, 2021 -- Cerecor has signed an exclusive license deal with the Sanford Burnham Prebys Medical Discovery Institute to develop and commercialize a worldwide immune checkpoint program.

The deal will allow Cerecor to expand its pipeline of immunology and immuno-oncology targets. Per the deal, Cerecor will pay Sanford Burnham Prebys an upfront payment, as well as additional payments based on achieving development, regulatory, and commercial milestones, sales-based royalties, and a share of sublicensing income.

In other business, Cerecor divested its noncore neurology pipeline assets, which are compounds used in CERC-301 and in the COMTi platform, including CERC-406, to Alto Neuroscience and ES Therapeutics. The company had said it planned to seek alternatives since the neurology assets were not core to its business. Cerecor will receive undisclosed initial payments and additional payments, and is entitled to royalty payments based on the net sales of CERC-301 as part of the divestures.

Cerecor licenses cytokine storm antibody from Kyowa Kirin
Cerecor has expanded an agreement with Kyowa Kirin for the exclusive worldwide rights to CERC-002, Kyowa Kirin's fully human anti-LIGHT (tumor necrosis...
Model Medicines partners with Sandford Prebys Medical
Artificial intelligence drug discovery software developer Model Medicines has signed a deal with Sanford Burnham Prebys Medical Discovery Institute to...
Improving melanoma immunotherapies by regulating Treg proliferation
A new pathway to regulating anti-tumor immunity and increasing the effectiveness of PD-1 therapies was identified by scientists at Sanford Burnham Prebys...

Copyright © 2021 scienceboard.net

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter